Remove 2020 Remove Competition Remove Specialization
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. In order to bring it to market, a special program called Risk Evaluation and Mitigation Strategy (REMS) had to be put in place, where only eligible patients could access the drug through a very strict process. Competition starts to heat up. Classic treatment options. About the author.

article thumbnail

It’s Time for Healthcare To Embrace Patient-Friendly Language

MedCity News

Increasingly, it’s a competitive differentiator – and it can help drive clinical improvements. As of October 2020, most health plans are required to disclose costs in a machine-readable format that also includes descriptions of typically cryptic billing codes in plain-language descriptions.

Patients 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

However, new MS drugs like Novartis ’ Gilenya, were going to soon enter the market and increase competition within the MS therapeutic landscape. Ferry explains, “The government deems that [special fraud alert] as public notice to the industry that they are concerned about these public programs.”.

article thumbnail

Launch Your Medical Device Sales Career with the Right Training and Job Placement

Rep-Lite

Medical device sales is a specialized field that involves selling medical and healthcare-related equipment, instruments, and devices to healthcare professionals, hospitals, and other healthcare facilities. billion in 2020 , and it continues to grow. What Is Medical Device Sales? Why Is Medical Device Sales a Rewarding Career?

article thumbnail

Briumvi may struggle to make headway in crowded multiple sclerosis market

Pharmaceutical Technology

Briumvi is the third approved injectable MS treatment directed against CD20 antigen expressed on B cells, with the other therapies being Kesimpta (ofatumumab, approved in 2020) and Ocrevus (ocrelizumab, approved in 2017). However, Briumvi is unlikely to appeal to patients who are already receiving Genentech’s Ocrevus or Novartis’s Kesimpta.

article thumbnail

Five IDNs to watch in 2023

Clarivate

In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.

article thumbnail

Nine for 2023, part one: a reflection on inflection

pharmaphorum

Some of the more resilient launches since 2020 have had these benefits to health systems. Compared to major primary care markets of the late 1990s/early 2000s, specialty care markets see more and earlier competitive launches, and the market share achieved by each launch after is progressively reduced.